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Randomisedtrials,andsystematicreviewsofsuchtrials,provide
the most reliable evidence about the effects of healthcare
interventions. Provided that there are enough participants,
randomisationshouldensurethatparticipantsintheintervention
and comparison groups are similar with respect to both known
and unknown prognostic factors. Differences in outcomes of
interest between the different groups can then in principle be
ascribed to the causal effect of the intervention.
1
Causal inferences from randomised trials can, however, be
underminedbyflawsindesign,conduct,analyses,andreporting,
leading to underestimation or overestimation of the true
intervention effect (bias).
2 However, it is usually impossible to
know the extent to which biases have affected the results of a
particular trial.
Systematicreviewsaimtocollateandsynthesiseallstudiesthat
meetprespecifiedeligibilitycriteria
3usingmethodsthatattempt
tominimisebias.Toobtainreliableconclusions,reviewauthors
mustcarefullyconsiderthepotentiallimitationsoftheincluded
studies. The notion of study “quality” is not well defined but
relates to the extent to which its design, conduct, analysis, and
presentation were appropriate to answer its research question.
Many tools for assessing the quality of randomised trials are
available,includingscales(whichscorethetrials)andchecklists
(whichassesstrialswithoutproducingascore).
4-7Untilrecently,
Cochrane reviews used a variety of these tools, mainly
checklists.
8 In 2005 the Cochrane Collaboration’s methods
groups embarked on a new strategy for assessing the quality of
randomised trials. In this paper we describe the collaboration’s
new risk of bias assessment tool, and the process by which it
was developed and evaluated.
Development of risk assessment tool
In May 2005, 16 statisticians, epidemiologists, and review
authors attended a three day meeting to develop the new tool.
Before the meeting, JPTH and DGA compiled an extensive list
of potential sources of bias in clinical trials. The items on the
list were divided into seven areas: generation of the allocation
sequence; concealment of the allocation sequence; blinding;
attrition and exclusions; other generic sources of bias; biases
specific to the trial design (such as crossover or cluster
randomisedtrials);andbiasesthatmightbespecifictoaclinical
specialty. For each of the seven areas, a nominated meeting
participant prepared a review of the empirical evidence, a
discussion of specific issues and uncertainties, and a proposed
set of criteria for assessing protection from bias as adequate,
inadequate, or unclear, supported by examples.
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RESEARCH METHODS & REPORTINGDuringthemeetingdecisionsweremadebyinformalconsensus
regarding items that were truly potential biases rather than
sources of heterogeneity or imprecision. Potential biases were
then divided into domains, and strategies for their assessment
were agreed, again by informal consensus, leading to the
creation of a new tool for assessing potential for bias. Meeting
participantsalsodiscussedhowtosummariseassessmentsacross
domains, how to illustrate assessments, and how to incorporate
assessments into analyses and conclusions. Minutes of the
meetingweretranscribedfromanaudiorecordinginconjunction
with written notes.
After the meeting, pairs of authors developed detailed criteria
for each included item in the tool and guidance for assessing
the potential for bias. Documents were shared and feedback
requested from the whole working group (including six who
could not attend the meeting). Several email iterations took
place, which also incorporated feedback from presentations of
theproposedguidanceatvariousmeetingsandworkshopswithin
the Cochrane Collaboration and from pilot work by selected
review teams in collaboration with members of the working
group. The materials were integrated by the co-leads into
comprehensive guidance on the new risk of bias tool. This was
published in February 2008 and adopted as the recommended
method throughout the Cochrane Collaboration.
9
Evaluation phase
A three stage project to evaluate the tool was initiated in early
2009.Aseriesoffocusgroupswasheldinwhichreviewauthors
whohadusedthetoolwereaskedtoreflectontheirexperiences.
Findings from the focus groups were then fed into the design
of questionnaires for use in three online surveys of review
authorswhohadusedthetool,reviewauthorswhohadnotused
the tool (to explore why not), and editorial teams within the
collaboration. We held a meeting to discuss the findings from
the focus groups and surveys and to consider revisions to the
first version of the risk of bias tool. This was attended by six
participants from the 2005 meeting and 17 others, including
statisticians, epidemiologists, coordinating editors and other
staff of Cochrane review groups, and the editor in chief of the
Cochrane Library.
The risk of bias tool
At the 2005 workshop the participants agreed the seven
principles on which the new risk of bias assessment tool was
based (box).
The risk of bias tool covers six domains of bias: selection bias,
performance bias, detection bias, attrition bias, reporting bias,
and other bias. Within each domain, assessments are made for
one or more items, which may cover different aspects of the
domain, or different outcomes. Table 1⇓ shows the
recommended list of items. These are discussed in more detail
in the appendix on bmj.com.
For each item in the tool, the assessment of risk of bias is in
two parts. The support for judgment provides a succinct free
text description or summary of the relevant trial characteristic
onwhichjudgmentsofriskofbiasarebasedandaimstoensure
transparency in how judgments are reached. For example, the
item about concealment of the randomised allocation sequence
would provide details of what measures were in place, if any,
toconcealthesequence.Informationforthesedescriptionswill
often come from a single published trial report but may be
obtained from a mixture of trial reports, protocols, published
comments on the trial, and contacts with the investigators. The
support for the judgment should provide a summary of known
facts, including verbatim quotes where possible. The source of
this information should be stated, and when there is no
information on which to base a judgment, this should be stated.
The second part of the tool involves assigning a judgment of
high, low, or unclear risk of material bias for each item. We
define material bias as bias of sufficient magnitude to have a
notable effect on the results or conclusions of the trial,
recognising the subjectivity of any such judgment. Detailed
criteria for making judgments about the risk of bias from each
of the items in the tool are available in the Cochrane
Handbook.
13 If insufficient detail is reported of what happened
in the trial, the judgment will usually be unclear risk of bias. A
judgment of unclear risk should also be made if what happened
in the trial is known but the associated risk of bias is
unknown—for example, if participants take additional drugs of
unknown effectiveness as a result of them being aware of their
intervention assignment. We recommend that judgments be
made independently by at least two people, with any
discrepancies resolved by discussion in the first instance.
Some of the items in the tool, such as methods for
randomisation, require only a single assessment for each trial
included in the review. For other items, such as blinding and
incompleteoutcomedata,twoormoreassessmentsmaybeused
because they generally need to be made separately for different
outcomes (or for the same outcome at different time points).
However, we recommend that review authors limit the number
of assessments used by grouping outcomes—for example, as
subjective or objective for the purposes of assessing blinding
of outcome assessment or as “patient reported at 6 months” or
“patient reported at 12 months” for assessing risk of bias due
to incomplete outcome data.
Evaluation of initial implementation
The first (2008) version of the tool was slightly different from
the one we present here. The 2008 version did not categorise
biases by the six domains (selection bias, performance bias,
etc); had a single assessment for blinding; and expressed risk
ofbiasintheformat‘”yes,”“no,”or“unclear”(referringtolack
of a risk) rather than as low, high, or unclear risk. The 2010
evaluation of the initial version found wide acceptance of the
need for the risk of bias tool, with a consensus that it represents
animprovementovermethodspreviouslyrecommendedbythe
Collaboration or widely used in systematic reviews.
Participants in the focus groups noted that the tool took longer
to complete than previous methods. Of 187 authors surveyed,
88%tooklongerthan10minutestocompletethenewtool,44%
longer than 20 minutes, and 7% longer than an hour, but 83%
consideredthetimetakenacceptable.Therewasconsensusthat
classifying items in the tool according to categories of bias
(selection bias, performance bias, etc) would help users, so we
introduced these. There was also consensus that assessment of
blinding should be separated into blinding of participants and
healthprofessionals(performancebias)andblindingofoutcome
assessment (detection bias) and that the phrasing of the
judgments about risk should be changed to low, high, and
unclear risk. The domains reported to be the most difficult to
assess were risk of bias due to incomplete outcome data and
selective reporting of outcomes. There was agreement that
improvedtrainingmaterialsandavailabilityofworkedexamples
would increase the quality and reliability of bias assessments.
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1. Do not use quality scales
Quality scales and resulting scores are not an appropriate way to appraise clinical trials. They tend to combine assessments of aspects of
the quality of reporting with aspects of trial conduct, and to assign weights to different items in ways that are difficult to justify. Both theoretical
considerations
10 and empirical evidence
11 suggest that associations of different scales with intervention effect estimates are inconsistent
and unpredictable
2. Focus on internal validity
The internal validity of a study is the extent to which it is free from bias. It is important to separate assessment of internal validity from that
of external validity (generalisability or applicability) and precision (the extent to which study results are free from random error). Applicability
depends on the purpose for which the study is to be used and is less relevant without internal validity. Precision depends on the number of
participants and events in a study. A small trial with low risk of bias may provide very imprecise results, with a wide confidence interval.
Conversely, the results of a large trial may be precise (narrow confidence interval) but have a high risk of bias if internal validity is poor
3. Assess the risk of bias in trial results, not the quality of reporting or methodological problems that are not directly related
to risk of bias
The quality of reporting, such as whether details were described or not, affects the ability of systematic review authors and users of medical
research to assess the risk of bias but is not directly related to the risk of bias. Similarly, some aspects of trial conduct, such as obtaining
ethical approval or calculating sample size, are not directly related to the risk of bias. Conversely, results of a trial that used the best possible
methods may still be at risk of bias. For example, blinding may not be feasible in many non-drug trials, and it would not be reasonable to
consider the trial as low quality because of the absence of blinding. Nonetheless, many types of outcome may be influenced by participants’
knowledge of the intervention received, and so the trial results for such outcomes may be considered to be at risk of bias because of the
absence of blinding, despite this being impossible to achieve
4. Assessments of risk of bias require judgment
Assessment of whether a particular aspect of trial conduct renders its results at risk of bias requires both knowledge of the trial methods
and a judgment about whether those methods are likely to have led to a risk of bias. We decided that the basis for bias assessments should
be made explicit, by recording the aspects of the trial methods on which the judgment was based and then the judgment itself
5. Choose domains to be assessed based on a combination of theoretical and empirical considerations
Empirical studies show that particular aspects of trial conduct are associated with bias.
212 However, these studies did not include all potential
sources of bias. For example, available evidence does not distinguish between different aspects of blinding (of participants, health professionals,
and outcome assessment) and is very limited with regard to how authors dealt with incomplete outcome data. There may also be topic
specific and design specific issues that are relevant only to some trials and reviews. For example, in a review containing crossover trials it
might be appropriate to assess whether results were at risk of bias because there was an insufficient “washout” period between the two
treatment periods
6. Focus on risk of bias in the data as represented in the review rather than as originally reported
Some papers may report trial results that are considered as at high risk of bias, for which it may be possible to derive a result at low risk of
bias. For example, a paper that inappropriately excluded certain patients from analyses might report the intervention groups and outcomes
for these patients, so that the omitted participants can be reinstated
7. Report outcome specific evaluations of risk of bias
Some aspects of trial conduct (for example, whether the randomised allocation was concealed at the time the participant was recruited)
apply to the trial as a whole. For other aspects, however, the risk of bias is inherently specific to different outcomes within the trial. For
example, all cause mortality might be ascertained through linkages to death registries (low risk of bias), while recurrence of cancer might
have been assessed by a doctor with knowledge of the allocated intervention (high risk of bias)
Presentation of assessments
Results of an assessment of risk of bias can be presented in a
table, in which judgments for each item in each trial are
presented alongside their descriptive justification. Table 2⇓
presents an example of a risk of bias table for one trial included
inaCochranereviewoftherapeuticmonitoringofantiretrovirals
for people with HIV.
14 Risks of bias due to blinding and
incomplete outcome data were assessed across all outcomes
within each included study, rather than separately for different
outcomes as will be more appropriate in some situations.
Presenting risk of bias tables for every study in a review can be
cumbersome, and we suggest that illustrations are used to
summarise the judgments in the main systematic review
document.Thefigure⇓providesanexample.Herethejudgments
apply to all meta-analyses in the review. An alternative would
be to illustrate the risk of bias for a particular meta-analysis (or
for a particular outcome if a statistical synthesis is not
undertaken), showing the proportion of information that comes
from studies at low, unclear, or high risk of bias for each item
in the tool, among studies contributing information to that
outcome.
Summary assessment of risk of bias
To draw conclusions about the overall risk of bias within or
across trials it is necessary to summarise assessments across
items in the tool for each outcome within each trial. In doing
this, review authors must decide which domains are most
important in the context of the review, ideally when writing
their protocol. For example, for highly subjective outcomes
such as pain, blinding of participants is critical. The way that
summaryjudgmentsofriskofbiasarereachedshouldbeexplicit
and should be informed by empirical evidence of bias when it
exists, likely direction of bias, and likely magnitude of bias.
Table3⇓providesasuggestedframeworkformakingsummary
assessments of the risk of bias for important outcomes within
and across trials.
Assessments of risk of bias and synthesis of
results
Summary assessments of the risk of bias for an outcome within
each trial should inform the meta-analysis. The two preferable
analytical strategies are to restrict the primary meta-analysis to
studies at low risk of bias or to present meta-analyses stratified
according to risk of bias. The choice between these strategies
should be based on the context of the particular review and the
balance between the potential for bias and the loss of precision
when studies at high or unclear risk of bias are excluded.
Meta-regression can be used to compare results from studies at
high and low risk of bias, but such comparisons lack power,
15
and lack of a significant difference should not be interpreted as
implying the absence of bias.
A third strategy is to present a meta-analysis of all studies while
providingasummaryoftheriskofbiasacrossstudies.However,
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RESEARCH METHODS & REPORTINGthis runs the risk that bias is downplayed in the discussion and
conclusions of a review, so that decisions continue to be based,
at least in part, on flawed evidence. This risk could be reduced
byincorporatingsummaryassessmentsintobroader,butexplicit,
measuresofthequalityofevidenceforeachimportantoutcome,
forexampleusingtheGRADEsystem.
16Thiscanhelptoensure
that judgments about the risk of bias, as well as other factors
affecting the quality of evidence (such as imprecision,
heterogeneity, and publication bias), are considered when
interpreting the results of systematic reviews.
17 18
Discussion
Discrepanciesbetweentheresultsofdifferentsystematicreviews
examining the same question
19 20 and between meta-analyses
and subsequent large trials
21 have shown that the results of
meta-analyses can be biased, which may be partly caused by
biased results in the trials they include. We believe our risk of
bias tool is one of the most comprehensive approaches to
assessing the potential for bias in randomised trials included in
systematicreviewsormeta-analyses.Inclusionofdetailsoftrial
conduct,onwhichjudgmentsofriskofbiasarebased,provides
greatertransparencythanpreviousapproaches,allowingreaders
to decide whether they agree with the judgments made. There
is continuing uncertainty, and great variation in practice, over
howtoassesspotentialforbiasinspecificdomainswithintrials,
how to summarise bias assessments across such domains, and
how to incorporate bias assessments into meta-analyses.
A recent study has found that the tool takes longer to complete
than other tools (the investigators took a mean of 8.8 minutes
per person for a single predetermined outcome using our tool
comparedwith1.5minutesforapreviousratingscaleforquality
of reporting).
22 The reliability of the tool has not been
extensively studied, although the same authors observed that
larger effect sizes were observed on average in studies rated as
at high risk of bias compared with studies at low risk of bias.
22
By explicitly incorporating judgments into the tool, we
acknowledge that agreements between assessors may not be as
high as for some other tools. However, we also explicitly target
the risk of bias rather than reported characteristics of the trial.
It would be easier to assess whether a drop-out rate exceeds
20% than whether a drop-out rate of 21% introduces an
importantriskofbias,butthereisnoguaranteethatresultsfrom
a study with a drop-out rate lower than 20% are at low risk of
bias. Preliminary evidence suggests that incomplete outcome
dataandselectivereportingarethemostdifficultitemstoassess;
kappa measures of agreement of 0.32 (fair) and 0.13 (slight)
respectively have been reported for these.
22 It is important that
guidance and training materials continue to be developed for
all aspects of the tool, but particularly these two.
We hope that widespread adoption and implementation of the
risk of bias tool, both within and outside the Cochrane
Collaboration,willfacilitateimprovedappraisalofevidenceby
healthcare decision makers and patients and ultimately lead to
betterhealthcare.Improvedunderstandingofthewaysinwhich
flaws in trial conduct may bias their results should also lead to
bettertrialsandmorereliableevidence.Riskofbiasassessments
shouldcontinuetoevolve,takingintoaccountanynewempirical
evidence and the practical experience of authors of systematic
reviews.
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RESEARCH METHODS & REPORTINGTables
Table 1| Cochrane Collaboration’s tool for assessing risk of bias (adapted from Higgins and Altman13)
Review authors’ judgment (assess as low,
unclear or high risk of bias) Support for judgment Source of bias Bias domain
Selection bias (biased allocation to interventions)
due to inadequate generation of a randomised
sequence
Describe the method used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it should
produce comparable groups
Random sequence
generation
Selection bias
Selection bias (biased allocation to interventions)
due to inadequate concealment of allocations
before assignment
Describe the method used to conceal the allocation sequence in
sufficient detail to determine whether intervention allocations
could have been foreseen before or during enrolment
Allocation concealment
Performance bias due to knowledge of the
allocated interventions by participants and
personnel during the study
Describe all measures used, if any, to blind trial participants and
researchers from knowledge of which intervention a participant
received. Provide any information relating to whether the intended
blinding was effective
Blinding of participants and
personnel*
Performance bias
Detection bias due to knowledge of the allocated
interventions by outcome assessment
Describe all measures used, if any, to blind outcome assessment
from knowledge of which intervention a participant received.
Provide any information relating to whether the intended blinding
was effective
Blinding of outcome
assessment*
Detection bias
Attrition bias due to amount, nature, or handling
of incomplete outcome data
Describe the completeness of outcome data for each main
outcome, including attrition and exclusions from the analysis.
State whether attrition and exclusions were reported, the numbers
in each intervention group (compared with total randomised
participants), reasons for attrition or exclusions where reported,
and any reinclusions in analyses for the review
Incomplete outcome data* Attrition bias
Reporting bias due to selective outcome
reporting
State how selective outcome reporting was examined and what
was found
Selective reporting Reporting bias
Bias due to problems not covered elsewhere State any important concerns about bias not covered in the other
domains in the tool
Anything else, ideally
prespecified
Other bias
*Assessments should be made for each main outcome or class of outcomes.
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RESEARCH METHODS & REPORTINGTable 2| Example of risk of bias table from a Cochrane review14
Support for judgment Authors’ judgment Bias
Quote: “Randomization was one to one with a block of size 6. The list of randomization was
obtained using the SAS procedure plan at the data statistical analysis centre”
Low risk Random sequence generation (selection bias)
The randomisation list was created at the statistical data centre, but further description of
allocation is not included
Unclear risk Allocation concealment (selection bias)
Open label High risk Blinding of participants and researchers
(performance bias)
Open label High risk Blinding of outcome assessment (detection bias)
Losses to follow-up were disclosed and the analyses were conducted using, firstly, a modified
intention to treat analysis in which missing=failures and, secondly, on an observed basis.
Although the authors describe an intention to treat analysis, the 139 participants initially
randomised were not all included; five were excluded (four withdrew and one had lung
cancer diagnosed). This is a reasonable attrition and not expected to affect results. Adequate
sample size of 60 per group was achieved
Low risk Incomplete outcome data (attrition bias)
All prespecified outcomes were reported Low risk Selective reporting (reporting bias)
No description of the uptake of the therapeutic drug monitoring recommendations by
physicians, which could result in performance bias
Unclear risk Other bias
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RESEARCH METHODS & REPORTINGTable 3| Approach to formulating summary assessments of risk of bias for each important outcome (across domains) within and across
trials (adapted from Higgins and Altman13)
Across trials Within a trial Interpretation Risk of bias
Most information is from trials at low risk of bias Low risk of bias for all key domains Bias, if present, is unlikely to alter the results
seriously
Low risk of bias
Most information is from trials at low or unclear risk
of bias
Low or unclear risk of bias for all key
domains
A risk of bias that raises some doubt about
the results
Unclear risk of bias
The proportion of information from trials at high risk
of bias is sufficient to affect the interpretation of
results
High risk of bias for one or more key
domains
Bias may alter the results seriously High risk of bias
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RESEARCH METHODS & REPORTINGFigure
Fig 1 Example presentation of risk of bias assessments for studies in a Cochrane review of therapeutic monitoring of
antiretroviral drugs in people with HIV
14
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